[go: up one dir, main page]

MA38078A1 - Dérivé de pyridine - Google Patents

Dérivé de pyridine

Info

Publication number
MA38078A1
MA38078A1 MA38078A MA38078A MA38078A1 MA 38078 A1 MA38078 A1 MA 38078A1 MA 38078 A MA38078 A MA 38078A MA 38078 A MA38078 A MA 38078A MA 38078 A1 MA38078 A1 MA 38078A1
Authority
MA
Morocco
Prior art keywords
pyridine derivative
prodrug
pharmaceutically acceptable
acceptable salt
urat1
Prior art date
Application number
MA38078A
Other languages
English (en)
Other versions
MA38078B1 (fr
Inventor
Akinobu Maruyama
Hirofumi Kamada
Mika Fujinuma
Susumu Takeuchi
Hiroshi Saitoh
Yoshimasa Takahashi
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA38078A1 publication Critical patent/MA38078A1/fr
Publication of MA38078B1 publication Critical patent/MA38078B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

Dérivé de pyridine représenté par la formule (i), promédicament de celui-ci, sel pharmaceutiquement acceptable du dérivé de pyridine ou du promédicament, ou solvate du dérivé de pyridine, du promédicament ou du sel pharmaceutiquement acceptable, qui est utile pour traiter ou prévenir les maladies associées à urat1 telles que la goutte, l'hyperuricémie, l'hypertension, les maladies rénales telles que la néphrite interstitielle, le diabète, l'artériosclérose et le syndrome de lesch-nyhan.
MA38078A 2012-11-14 2013-11-13 Dérivé de pyridine MA38078B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012250661 2012-11-14
PCT/JP2013/080706 WO2014077285A1 (fr) 2012-11-14 2013-11-13 Dérivé de pyridine

Publications (2)

Publication Number Publication Date
MA38078A1 true MA38078A1 (fr) 2016-09-30
MA38078B1 MA38078B1 (fr) 2017-04-28

Family

ID=50731196

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38078A MA38078B1 (fr) 2012-11-14 2013-11-13 Dérivé de pyridine

Country Status (36)

Country Link
US (2) US9637469B2 (fr)
EP (2) EP3339302A1 (fr)
JP (2) JP5774238B2 (fr)
KR (1) KR20150082194A (fr)
CN (2) CN104797570B (fr)
AR (1) AR093468A1 (fr)
AU (2) AU2013345894B2 (fr)
BR (1) BR112015010977A2 (fr)
CA (1) CA2891408A1 (fr)
CL (1) CL2015001279A1 (fr)
CY (1) CY1120127T1 (fr)
DK (1) DK2944633T3 (fr)
ES (1) ES2662444T3 (fr)
HR (1) HRP20180451T1 (fr)
HU (1) HUE037736T2 (fr)
IL (2) IL238539A (fr)
LT (1) LT2944633T (fr)
MA (1) MA38078B1 (fr)
ME (1) ME03016B (fr)
MX (1) MX2015003672A (fr)
NO (1) NO2944633T3 (fr)
NZ (1) NZ708031A (fr)
PE (1) PE20150974A1 (fr)
PH (1) PH12015501037A1 (fr)
PL (1) PL2944633T3 (fr)
PT (1) PT2944633T (fr)
RS (1) RS57090B1 (fr)
RU (1) RU2640588C2 (fr)
SA (1) SA515360431B1 (fr)
SG (2) SG10201705852PA (fr)
SI (1) SI2944633T1 (fr)
SM (1) SMT201800322T1 (fr)
TW (1) TWI666205B (fr)
UA (1) UA117359C2 (fr)
WO (1) WO2014077285A1 (fr)
ZA (1) ZA201503322B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3144306B1 (fr) * 2014-05-13 2017-11-15 Teijin Pharma Limited Dérivé pyrazine
AR100404A1 (es) * 2014-05-13 2016-10-05 Teijin Pharma Ltd Polimorfos cristalinos de un derivado de piridina y método para producirlos
MX2018011214A (es) * 2016-03-15 2019-03-28 Bayer Cropscience Ag Sulfonamidas sustituidas para controlar plagas animales.
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
EP3466946B1 (fr) * 2016-05-23 2023-08-30 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Thiophène, son procédé de fabrication, et application pharmaceutique correspondante
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
AU2018207776B2 (en) 2017-01-10 2021-06-17 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
US11083199B2 (en) 2017-01-10 2021-08-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
CN108658879A (zh) * 2017-03-29 2018-10-16 天津药物研究院有限公司 一种urat1抑制剂及其制备方法和用途
CN109251184B (zh) * 2017-07-13 2021-06-15 浙江海正药业股份有限公司 一种2-三氟甲基苯磺酰胺类衍生物的医药用途
SMT202200134T1 (it) 2018-03-08 2022-05-12 Incyte Corp Composti di amminopirazindiolo come inibitori di pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
EP4055010A1 (fr) 2019-11-07 2022-09-14 Bayer Aktiengesellschaft Sulfonyl amides substitués pour lutter contre des animaux nuisibles
EP4175961A1 (fr) 2020-07-02 2023-05-10 Bayer Aktiengesellschaft Dérivés d'hétérocyclène utiles en tant qu'agents de lutte contre les nuisibles
CN114315729B (zh) * 2021-12-09 2024-01-26 大连理工大学 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用
WO2025026738A1 (fr) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Dérivés de 6-[5-(éthylsulfonyl)-1-méthyl-1h-imidazol-4-yl]-7-méthyl-3-(pentafluoroéthyl)-7h-imidazo [4,5-c]pyridazine en tant que pesticides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599032A (en) * 1977-03-04 1981-09-30 May & Baker Ltd Imidazole derivatives having herbicidal activity
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
PL149675B1 (pl) * 1986-03-10 1990-03-31 Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5
US4770689A (en) * 1986-03-10 1988-09-13 Janssen Pharmaceutica N.V. Herbicidal imidazole-5-carboxylic acid derivatives
DD260928A5 (de) * 1986-06-06 1988-10-12 Ciba-Geigy Ag,Ch Verfahren zur herstellung neuer aralkylimidizolderivate
MY100938A (en) 1986-06-06 1991-05-31 Ciba Geigy Ag Arylkylimidazole derivatives.
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
CA2416946A1 (fr) 2000-07-28 2003-01-22 Sumitomo Pharmaceuticals Co., Ltd. Derives du pyrrole
CN100457750C (zh) 2001-02-22 2009-02-04 帝人株式会社 苯并[b]噻吩衍生物及其制备方法
AU2003902828A0 (en) * 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
KR101291643B1 (ko) * 2007-11-27 2013-08-01 아디아 바이오사이언스즈 인크. 신규한 화합물 및 조성물과 사용 방법
US8450500B2 (en) * 2008-06-04 2013-05-28 Synta Pharmaceuticals Corp. Pyrrole compounds that modulate HSP90 activity
EP2328879A4 (fr) 2008-09-04 2012-05-09 Ardea Biosciences Inc Composés, compositions, et procédés d'utilisation correspondants pour moduler des taux d'acide urique
JP2010202575A (ja) 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
BR112012000606A2 (pt) * 2009-07-10 2016-11-22 Brigham & Womens Hospital análogos de etomidato que não inibem a síntese de esteróides adrenocorticais
CN102035579B (zh) * 2009-09-28 2014-09-03 夏普株式会社 信息反馈方法和用户设备
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP5485811B2 (ja) * 2010-06-23 2014-05-07 株式会社ジャパンディスプレイ 双方向シフトレジスタ、及びこれを用いた画像表示装置
BR112013003358A2 (pt) * 2010-08-11 2016-07-12 Millennium Pharm Inc heteroaris e seus usos

Also Published As

Publication number Publication date
SMT201800322T1 (it) 2018-07-17
CA2891408A1 (fr) 2014-05-22
EP3339302A1 (fr) 2018-06-27
NO2944633T3 (fr) 2018-06-30
ZA201503322B (en) 2016-01-27
TWI666205B (zh) 2019-07-21
PT2944633T (pt) 2018-05-09
JP2015091865A (ja) 2015-05-14
CL2015001279A1 (es) 2015-06-26
IL243193A0 (en) 2016-02-29
EP2944633B1 (fr) 2018-01-31
US20150284358A1 (en) 2015-10-08
MA38078B1 (fr) 2017-04-28
NZ708031A (en) 2018-04-27
IL238539A (en) 2017-11-30
US20170190694A1 (en) 2017-07-06
CN107721931A (zh) 2018-02-23
UA117359C2 (uk) 2018-07-25
SA515360431B1 (ar) 2017-11-15
HUE037736T2 (hu) 2018-09-28
PH12015501037A1 (en) 2015-07-27
SI2944633T1 (en) 2018-06-29
CN104797570A (zh) 2015-07-22
LT2944633T (lt) 2018-03-12
US9637469B2 (en) 2017-05-02
DK2944633T3 (en) 2018-03-12
HK1211940A1 (en) 2016-06-03
MX2015003672A (es) 2015-06-15
KR20150082194A (ko) 2015-07-15
WO2014077285A1 (fr) 2014-05-22
AR093468A1 (es) 2015-06-10
HRP20180451T1 (hr) 2018-06-01
PL2944633T3 (pl) 2018-08-31
RS57090B1 (sr) 2018-06-29
JPWO2014077285A1 (ja) 2017-01-05
RU2015122698A (ru) 2017-01-10
PE20150974A1 (es) 2015-07-04
TW201422603A (zh) 2014-06-16
ME03016B (fr) 2018-10-20
AU2013345894B2 (en) 2017-05-25
JP5774238B2 (ja) 2015-09-09
AU2017204665A1 (en) 2017-07-27
RU2640588C2 (ru) 2018-01-10
CY1120127T1 (el) 2018-12-12
EP2944633A1 (fr) 2015-11-18
SG10201705852PA (en) 2017-08-30
JP6293068B2 (ja) 2018-03-14
CN104797570B (zh) 2017-11-07
AU2013345894A9 (en) 2015-11-12
EP2944633A4 (fr) 2016-01-06
ES2662444T3 (es) 2018-04-06
BR112015010977A2 (pt) 2017-07-11
SG11201503770VA (en) 2015-06-29
AU2013345894A1 (en) 2015-05-21
IL238539A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
MA38078B1 (fr) Dérivé de pyridine
CR20220251A (es) Nuevos derivados de metilquinazolinona
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
EA202193015A1 (ru) Ингибиторы cdk
EA202192029A1 (ru) Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201991884A3 (ru) Ингибиторы g12c kras
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
BR112017006251A2 (pt) novos compostos
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
MY181731A (en) Azole benzene derivative
EA201270816A1 (ru) Производные бензамида и их применение в качестве ингибиторов hsp90
EA201500575A1 (ru) Транс-4-{2-[4-(2,3-дихлорфенил)пиперазин-1-ил]этил}-n,n-диметилкарбамоилциклогексиламин для лечения негативных симптомов шизофрении
MX2016014939A (es) Derivados de carboxamida.
MX376202B (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
EA201692298A1 (ru) Производные карбоксамидов
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
AU2018264313A1 (en) Indolizine derivatives and application thereof in medicine
EA201290610A1 (ru) Сульфоновые соединения в качестве лигандов 5-htрецептора
PH12016502223A1 (en) Pyrazine derivatives
EA201691265A1 (ru) Соединения агонисты gpr142